Of the 1731 patients in the rivaroxaban arm of this study, 245 patients had a weight > 100
kg but further classification into weight > 120 kg or BMI > 40 kg/m SP 2 sp was not …

Patients with high body weight are at increased risk of developing atrial fibrillation (AF) or
venous thromboembolism (VTE) and are often treated with antithrombotic drugs. 1 Direct …

Methods: After institutional review board approval, we conducted a retrospective chart
review for 1 year period (Jan 1, 2020-Dec 31, 2020) on all patients>/= 18 years of age who …

Direct oral anticoagulants (DOACs) are widely used as first-line treatment for pulmonary
embolism (PE) in patients without contraindications [1]; however, limited data exists on the …

Background: Anticoagulation (AC) is the cornerstone of treatment for venous
thromboembolism (VTE). Direct oral anticoagulants (DOACs) have become the standard of …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

Background. Obesity is a major epidemic affecting all age groups in the USA. It has been
associated with venous thromboembolism (VTE), which requires prolonged anticoagulation …

Background: Due to limited enrollment in landmark trials of patients with a BMI> 30 or
weight> 100 kg for apixaban and rivaroxaban, the International Society of Thrombosis and …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Abstract Background Direct oral anticoagulants (DOACs) are often used in patients with
atrial fibrillation or flutter instead of warfarin and although supporting evidence is limited …